SynthesisBMC nephrology2025
Therapeutic strategies for olfactory impairment in patients with chronic kidney disease: a systematic review.
Synthesis in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOlfactory impairment is often considered a minor complication of chronic kidney disease (CKD), carrying important consequences for nutrition, safety, and overall quality of life. While several therapeutic strategies have been introduced in other populations, their effectiveness in the context of CKD remains poorly understood. This systematic review aimed to evaluate current evidence on the treatment of olfactory impairment in CKD patients, including those undergoing dialysis or kidney transplantation (KT).
methodsA comprehensive literature search was conducted across PubMed, Scopus, and Web of Science. Studies were included if they assessed therapeutic interventions targeting olfactory impairment in CKD patients. Data on study design, population, olfactory assessments, interventions, and outcomes were extracted and quality-assessed using the Effective Public Health Practice Project (EPHPP) tool.
resultsEight studies, published from 1987 to 2023, involving 469 CKD patients were included, spanning pre-dialysis, hemodialysis (HD), peritoneal dialysis (PD), and KT populations. Olfactory impairment was highly prevalent across all groups, affecting odor identification and discrimination. While KT offered the most complete recovery, dialysis had mixed effects, with limited improvement in olfactory thresholds. Among treatments, intranasal theophylline and curcumin showed partial efficacy, while olfactory training demonstrated the most consistent improvements in subjective and objective measures.
conclusionOlfactory impairment in CKD is a complex complication. Among available approaches, olfactory training stands out as a promising, non-pharmacologic option. Future clinical trials are essential to validate and refine treatment strategies tailored to the distinct metabolic and neurological challenges of CKD.Incorporating routine screening and targeted mannagement of olfactory impairment into nephrology practice may enhance overall patient care, nutritional status, and quality of life. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.